Coverage Rationale

The following is proven and medically necessary:
- Injection of local anesthetics and/or steroids used as occipital nerve blocks for treating pain due to malignancy involving the head and neck

The following are unproven and not medically necessary for diagnosing and/or treating occipital neuralgia or headaches, including migraine and Cervicogenic Headaches, due to insufficient evidence of efficacy:
- Injection of local anesthetics and/or steroids, used as occipital nerve blocks
- Neurostimulation or electrical stimulation
- Occipital neurectomy
- Partial posterior intradural C1-C3 rhizotomy
- Radiofrequency ablation (thermal or pulsed) or denervation
- Rhizotomy of C1-C3 spinal dorsal roots
- Surgical decompression of second cervical nerve root and ganglion
- Surgical decompression of the greater occipital nerve

Documentation Requirements

Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The documentation requirements outlined below are used to assess whether the member meets the clinical criteria for coverage but do not guarantee coverage of the service requested.

<table>
<thead>
<tr>
<th>CPT Code*</th>
<th>Required Clinical Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>64405</td>
<td>Medical notes documenting all of the following:</td>
</tr>
<tr>
<td></td>
<td>History and physical findings</td>
</tr>
</tbody>
</table>
Occipital Neuralgia and Headache Treatment

Identification of the problem including diagnosis, precipitating events
- Frequency, duration and intensity of pain
- Previous response to therapies
- Laboratory

*For code description, see the Applicable Codes section.

Definitions

Cervicogenic Headache: Referred pain perceived in the head from a source in the neck. In the case of cervicogenic headache, the cause is a disorder of the cervical spine and its component bony, disc and/or soft tissue elements. (American Migraine Foundation, 2016)

Neurectomy: Partial or total excision or resection of a nerve. (Taber’s Medical Dictionary)

Rhizotomy: Surgical section of a nerve root to relieve pain. (Taber’s Medical Dictionary)

Applicable Codes

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.

<table>
<thead>
<tr>
<th>CPT Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>63185</td>
<td>Laminectomy with rhizotomy; 1 or 2 segments</td>
</tr>
<tr>
<td>63190</td>
<td>Laminectomy with rhizotomy; more than 2 segments</td>
</tr>
<tr>
<td>64405</td>
<td>Injection(s), anesthetic agent(s) and/or steroid; greater occipital nerve</td>
</tr>
<tr>
<td>64553</td>
<td>Percutaneous implantation of neurostimulator electrode array; cranial nerve</td>
</tr>
<tr>
<td>64555</td>
<td>Percutaneous implantation of neurostimulator electrode array; peripheral nerve (excludes sacral nerve)</td>
</tr>
<tr>
<td>64568</td>
<td>Incision for implantation of cranial nerve (e.g., vagus nerve) neurostimulator electrode array and pulse generator</td>
</tr>
<tr>
<td>64570</td>
<td>Removal of cranial nerve (e.g., vagus nerve) neurostimulator electrode array and pulse generator</td>
</tr>
<tr>
<td>64575</td>
<td>Incision for implantation of neurostimulator electrode array; peripheral nerve (excludes sacral nerve)</td>
</tr>
<tr>
<td>64590</td>
<td>Insertion or replacement of peripheral or gastric neurostimulator pulse generator or receiver, direct or inductive coupling</td>
</tr>
<tr>
<td>64633</td>
<td>Destruction by neurolytic agent, paravertebral facet joint nerve(s), with imaging guidance (fluoroscopy or CT); cervical or thoracic, single facet joint</td>
</tr>
<tr>
<td>64634</td>
<td>Destruction by neurolytic agent, paravertebral facet joint nerve(s), with imaging guidance (fluoroscopy or CT); cervical or thoracic, each additional facet joint (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>64722</td>
<td>Decompression; unspecified nerve(s) (specify)</td>
</tr>
<tr>
<td>64744</td>
<td>Transection or avulsion of; greater occipital nerve</td>
</tr>
<tr>
<td>64771</td>
<td>Transection or avulsion of other cranial nerve, extradural</td>
</tr>
<tr>
<td>64999</td>
<td>Unlisted procedure, nervous system</td>
</tr>
</tbody>
</table>

CPT® is a registered trademark of the American Medical Association
### Description of Services

Cervicogenic headache and occipital neuralgia are conditions whose diagnosis and treatment have been gradually refined over the last several years. This terminology has come to refer to specific types of unilateral headache thought to arise from impingement or entrapment of the occipital nerves and/or the upper spinal vertebrae. Compression and injury of the occipital nerves within the muscles of the neck and compression of the second and third cervical nerve roots are generally felt to be responsible for the symptoms, including unilateral and occasionally bilateral head, neck, and arm pain. The criteria for diagnosis of these entities currently include those of the International Headache Society (IHS) and the Cervicogenic Headache International Study Group.

Various treatments have been advocated for cervicogenic headache and occipital neuralgia. Oral analgesics and anti-inflammatory agents are effective for some patients, but there is a population of patients who do not experience pain relief with these medications. Local injections or nerve blocks, epidural steroid injections, radiofrequency ablation of the planum nuchae, electrical stimulation, rhizotomy, ganglionectomy, nerve root decompression, discectomy and spinal fusion have all been investigated in the treatment of headache and occipital neuralgia.

Since medications provide only temporary relief and may cause side effects, surgical treatments such as occipital neurectomy and nerve decompression for migraine and other headaches have been developed as a potential means to permanently prevent or to produce long-term remissions from headaches.

Radiofrequency ablation is performed percutaneously. During the procedure, an electrode that generates heat produced by radio waves is used to create a lesion in a sensory nerve with the intent of inhibiting transmission of pain signal from the sensory nerve to the brain.

Neurostimulation or electrical stimulation is commonly used for control of chronic pain. Electrical stimulation can be delivered in 3 ways: transcutaneously, percutaneously, and using implantable devices. Peripherally implanted nerve stimulation entails the placement of electrodes on or near a selected peripheral nerve. Targets for stimulation include occipital nerves, auriculotemporal nerves, supraorbital nerves, and sphenopalatine ganglia.

### Clinical Evidence

#### Diagnostic Occipital Nerve Blocks

Occipital nerve blocks have been advocated as a diagnostic test for cervicogenic headache and occipital neuralgia. However, criteria and standards for diagnostic occipital nerve blocks remain to be defined. There are no well-designed clinical trials that clearly indicate that injection of occipital nerves can be used as a specific diagnostic test for headaches and occipital neuralgia.

See the following website for diagnostic criteria for cervicogenic headache and occipital neuralgia: The International Classification of Headache Disorders, 3rd edition. Available at: [http://www.ihs-headache.org/ichd-guidelines](http://www.ihs-headache.org/ichd-guidelines). (Accessed May 6, 2020)

#### Therapeutic Occipital Nerve Blocks

A systematic review and meta-analysis was conducted by Shauly et al. (2019) to determine the efficacy of greater occipital nerve block in the treatment of chronic migraine headaches. Nine studies were analyzed that reported mean number of

### HCPCS Code

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>L8679</td>
<td>Implantable neurostimulator, pulse generator, any type</td>
</tr>
<tr>
<td>L8680</td>
<td>Implantable neurostimulator electrode, each</td>
</tr>
<tr>
<td>L8685</td>
<td>Implantable neurostimulator pulse generator, single array, rechargeable, includes extension</td>
</tr>
</tbody>
</table>

### Diagnosis Code

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>C76.0</td>
<td>Malignant neoplasm of head, face and neck</td>
</tr>
<tr>
<td>G89.3</td>
<td>Neoplasm related pain (acute) (chronic)</td>
</tr>
</tbody>
</table>
headache days per month in both intervention and control groups. The study included 440 participants (intervention, n = 224; control, n = 216). Six of the included randomized controlled trials reported intervention treatment as either bupivacaine or lidocaine versus saline injection. Three of the included randomized controlled trials reported intervention treatment as corticosteroid in addition to bupivacaine or lidocaine versus bupivacaine or lidocaine with saline as the control group. Eight of the studies that were analyzed reported the mean headache days per month in both intervention and control groups. A total of 417 patients were studied, with a pooled mean difference of −3.6 headache days (95 percent CI, −1.39 to −5.81 headache days; p < 0.00001). Pooled mean difference in pain scores of -2.2 (95 percent CI, -1.56 to -2.84) also demonstrated a decrease in headache severity compared with controls (p < 0.0121). Seven of the studies assessed reported mean visual analogue scale pain scores. Pooled mean difference in pain scores of −2.2 (95 percent CI, −1.56 to −2.84; p = 0.0121). Two studies also reported patients that experienced a greater than 50 percent reduction in headache frequency. Risk ratios were calculated in these two studies, and the average risk ratio was found to be 0.76 (95 percent CI, 0.97 to 0.55; p < 0.00001). The authors concluded that greater occipital nerve blocking should be recommended for use in migraine patients, particularly those that may require future surgical intervention. The block may act as stepping stone for patients experiencing migraine headache because of its usefulness for potentially assessing surgical candidates for nerve decompression. The included studies had some limitations. For one, patients in the control group in three of these studies were also given bupivacaine or lidocaine, whereas the intervention included corticosteroids. Variations between the control and intervention groups may skew the results of the meta-analysis. Another limitation of this study is the quality of included studies. Most of the included studies exhibited a relatively small sample population. Clinical trials with a much larger sample population and longer period of observation should be conducted.

Ozer et al. (2019) performed a study aimed to evaluate the efficacy of greater occipital nerve (GON) and supraorbital nerve (SON) blockade with local anesthetics for the preventive treatment of migraine without aura. Eighty-seven patients diagnosed with migraine without aura were included in the study and randomly divided. One group was injected with 1% lidocaine; the other group was injected with 0.9% saline. GON and SON injections were done bilaterally. The injections were repeated weekly for 3 weeks. Patients were followed up for 2 months to assess clinical response. Seventy-one patients completed the study. After 2 months, the number of headache days decreased from 12.8 ± 10.9 to 5.3 ± 7.4, and VAS decreased from 8.3 ± 1.0 to 5.5 ± 1.9 in the blockage group. The number of headache days decreased from 12.4 ± 10.3 to 7.5 ± 7.2 and VAS decreased from 8.2 ± 1.1 to 7.4 ± 1.3 in the placebo group. Response was seen in 65.1% of the patients in the blockade group (65.4% for episodic migraine, 64.7% for chronic migraine) and 28.6% of the patients in the placebo group. The authors reported that the results suggest that GON and SON blockade with lidocaine was more effective than the placebo in the prophylactic treatment of both episodic and chronic migraine.

A retrospective study was performed by Gonen et al. (2019) which included 51 patients with episodic and chronic CH that underwent greater occipital nerve (GON) blockade with a single dose of rapid and long-acting steroid injection without additional prophylactic treatment. Pain assessment was performed using the Visual Analog Scale (VAS). The patients were asked to keep a record of the frequency, severity, and duration of attacks after GON blockade. In 28 (54.9%) patients, no attack occurred after GON blockade and cluster bouts were halted. Mean duration of attacks was 86.67 ± 37.45 min before the treatment. In the 23 patients that had at least one attack after GON blockade, the mean duration of attacks was 31.73 ± 36.10 min between post-treatment days 0-3, 29.35 ± 40.49 min between post-treatment days 4-10, 28.48 ± 42.17 min between post-treatment days 11-28, and 35.65 ± 46.55 min after the post-treatment day 28 (p < 0.001). Between post-treatment days 0–3, the VAS score was 0 in 70.6% (n = 36), between 1 and 5 in 13.7% (n = 7), and between 6 and 10 in 15.7% (n = 8) of the patients. Between post-treatment days 4–10, the VAS score was 0 in 76.5% (n = 39), between 1 and 5 in 7.8% (n = 4), and between 6 and 10 in 15.7% (n = 8) of the patients. Between post-treatment days 11–28, the VAS score was 0 in 80.4% (n = 41), between 1 and 5 in 3.9% (n = 2), and between 6 and 10 in 15.7% (n = 8) of the patients. After the post-treatment day 28, the VAS score was 0 in 86.3% (n = 44) and between 6 and 10 in 13.7% (n = 7) of the patients. The authors concluded that GON blockade is a practical, reliable, and cost-effective treatment option for patients with episodic and chronic CH. The study is limited by its retrospective observations and small sample size.

A 2019 Hayes Health Technology Assessment report focused on the efficacy and safety of greater occipital nerve block (GONB) for the preventive treatment of chronic migraine (CM) headaches in patients with an inadequate response to standard care. The overall quality of the body of evidence was rated as low due to individual study limitations, some inconsistencies in outcomes, and imprecision in some comparisons or outcomes examined in only a few studies or a single study. GONB with injection of a local anesthetic is relatively safe and may improve most headache outcomes over the short term compared with placebo. Little to no evidence meeting inclusion criteria was found around benefit of chronic use of this therapy. There is a
need for additional, larger, well-designed controlled trials with longer follow-up to adequately determine the optimal clinical role of GONB in the preventive treatment of CM.

There was small or insufficient evidence for the use of GONB for the prevention of debilitating symptoms of episodic migraine (EM) or transformed migraine in adult patients who do not respond adequately to standard therapy (Hayes, 2019b).

A 2019 Hayes report on Nerivio Migra for acute treatment of migraines found low quality evidence for the use of greater occipital nerve block (GONB) for the prevention of debilitating symptoms of chronic migraine (CM) in adult patients who do not respond adequately to standard therapy. GONB with injection of a local anesthetic is relatively safe and may improve most headache outcomes over the short term compared with placebo. Little to no evidence was found around benefit of chronic use of this therapy. There is a need for additional, larger, well-designed controlled trials (Hayes, 2019c).

A systematic review and meta-analysis were conducted by Zhang et al. (2018) to investigate the impact of greater occipital nerve (GON) block on pain management of migraine. Seven randomized controlled trials (RCTs) (n=323) assessing the efficacy of GON block versus placebo for migraine were included. The primary outcome was pain intensity. The authors concluded that compared with control intervention in migraine patients, GON block intervention can significantly reduce pain intensity and analgesic medication consumption but has no remarkable impact on headache duration and adverse events. The analysis was based on only seven RCTs, with relatively small sample size (n < 100) and short follow-up time.

A prospective-randomized controlled study was conducted by Korucu et al. (2018) to evaluate the effectiveness of a greater occipital nerve (GON) blockade against a placebo and classical treatments (non-steroidal anti-inflammatory drugs and metoclopramide) among patients who were admitted to the emergency department (ED) with acute migraine headaches. Sixty patients were randomly assigned to 3 treatment groups: the GON blockade group (nerve blockade with bupivacaine), the placebo group (injection of normal saline into the GON area), and the intravenous (IV) treatment group (IV dexketoprofen and metoclopramide). The pain severity was assessed at 5, 15, 30, and 45 minutes with a 10-point pain scale score (PSS). The mean decreases in the 5-, 15-, 30-, and 45-minutes PSS scores were greater in the GON blockade group than in the dexketoprofen and placebo groups. The authors concluded that a GON blockade was as effective as an IV dexketoprofen + metoclopramide treatment and superior to a placebo in patients with acute migraine headaches. No follow-up was noted.

Allen et al. (2018) performed a retrospective cohort study to assess the efficacy of greater occipital nerve (GON) block in acute treatment of migraine headache, with a focus on pain relief. The study was undertaken between January 2009 and August 2014 and included patients who underwent at least 1 GON block and attended at least 1 follow-up appointment. Change in the 11-point numeric pain rating scale (NPRS) was used to assess the response to GON block. Response was defined as "minimal" (<30% NPRS point reduction), "moderate" (31-50% NPRS point reduction), or "significant" (>50% NPRS point reduction). A total of 562 patients met inclusion criteria. Of these 562, 459 patients (82%) rated their response to GON block as moderate or significant. No statistically significant relationship existed between previous treatment regimens and response to GON block. GON block was equally effective across the different age and sex groups. The authors concluded that greater occipital block seems to be an effective option for acute management of migraine headache, with promising reductions in pain scores.

Tang et al. (2017) conducted a systematic review and meta-analysis to explore the efficacy of greater occipital nerve (GON) block in migraine patients. Six randomized controlled trials (RCTs) assessing the efficacy of GON block versus placebo in migraine patients were included. Compared with control intervention in migraine patients, GON block intervention was found to significantly reduce pain score, number of headache days, and medication consumption but demonstrated no influence on duration of headache per four weeks. The authors concluded that GON block intervention can significantly alleviate pain, reduce the number of headache days and medication consumption, but have no significant influence on the duration of headache per four weeks for migraine patients. The short-term follow-up did not allow for assessment of intermediate and long term outcomes.

A systematic review was conducted by Yang et al. (2016) to evaluate the clinical efficacy and safety of occipital nerve stimulation (ONS) for treating migraine. Five randomized controlled trials, 4 retrospective studies, and one prospective study met the inclusion criteria. The authors concluded that results from the retrospective studies and case series indicated that ONS significantly reduced the pain intensity and the number of days with headache in patients with migraine. The evidence of ONS efficacy established by randomized controlled trials was limited. Improvement was noted in the migraine disability assessment (MIDAS) score and SF-36 score at follow-up. The mean complication incidence of ONS was 66% for the reviewed studies. The
Gul et al. (2017) evaluated the efficacy of greater occipital nerve (GON) blockade in patients with chronic migraine (CM) in a randomized control study. The study included 44 CM patients who were randomly divided into two groups; group A (bupivacaine) and group B (placebo). GON blockade was administered four times (once per week) with bupivacaine or saline. After 4 weeks of treatment, patients were followed up for 3 months, and findings were recorded once every month for comparing each month's values with the pretreatment values. The primary endpoint was the difference in the frequency of headache (headache days/month). The Visual Analogue Scale (VAS) pain scores were also recorded. No severe adverse effects were reported. Group A showed a significant decrease in the frequency of headache and VAS scores at the first, second, and third months of follow-up. Group B showed a significant decrease in the frequency of headache and VAS scores at the first month of follow-up, but second and third months of follow-up showed no significant difference. The authors concluded that their results suggest that GON blockade with bupivacaine was superior to placebo, has long-lasting effect than placebo, and was found to be effective for the treatment of CM. More studies are needed to better define the safety and cost-effectiveness of GON blockade in chronic migraine.

Cuadrado et al. (2017) assessed the short-term clinical efficacy of greater occipital nerve (GON) anesthetic blocks in chronic migraine (CM) in a double-blind, randomized, placebo-controlled clinical trial. Thirty-six women with CM were treated either with bilateral GON block with bupivacaine 0.5% (n = 18) or a sham procedure with normal saline (n = 18). Headache frequency was recorded a week after and before the procedure. Pressure pain thresholds (PPTs) were measured in cephalic points (supraorbital, infraorbital and mental nerves) and extracephalic points (hand, leg) just before the injection (T0), one hour later (T1) and one week later (T2). Anesthetic block was superior to placebo in reducing the number of days per week with moderate-to-severe headache, or any headache. Overall, PPTs increased after anesthetic block and decreased after placebo; after the intervention, PPT differences between baseline and T1/T2 among groups were statistically significant for the supraorbital and infraorbital sites. The authors concluded that GON anesthetic blocks appear to be effective in the short term in CM, as measured by a reduction in the number of days with moderate-to-severe headache or any headache during the week following injection. This study was limited by its heterogeneous patient population and small sample size.

A Hayes December 2019 report for the use of anesthetic-based injections for individuals with cervicogenic headache found overall low-quality body of evidence suggesting that anesthetic-based injections provide superior pain relief compared with placebo and similar pain relief compared with more invasive treatments. The report concluded that there remains uncertainty regarding the duration of pain relief, the optimal formulation of anesthetic-based injections, the comparative effectiveness and safety versus conservative treatments, and patient selection criteria. For the use of anesthetic-based injections in patients with occipital neuralgia, the report found very-low-quality body of evidence suggesting that anesthetics plus steroid injections provide inferior pain relief compared with more invasive injection (Hayes, 2019a).

Okmen et al. (2016) evaluated six months of results from repeated greater occipital nerve blocks (GON). A standard 2 mL of 0.5% Bupivacaine GON blockage once a week for 4 weeks was applied. The Visual Analog Scale (VAS) scores, the number of migraine attacks and the Migraine Disability Assessment Questionnaire (MIDAS) scores were reported. The patients were not allowed to use medication for prophylaxis, and Ibuprofen was prescribed for any migraine attacks. The initial mean number of attacks per month before starting treatment was 8.33±2.31. After treatment, the initial MIDAS mean was found to be 2.82 per month; this declined to 1.47 in 3rd and was 1.50 in the 6th month. The mean VAS scores were recorded as follows for each month: 6.28 ± 1.24, 3.13 ± 0.97, 2.55 ± 1.19, 2.35 ± 1.26, 2.38 ± 1.20 and 2.48 ± 1.30, respectively. This difference was noted to be statistically significant. The authors concluded that GON blockage with 2mL of 0.5% Bupivacaine can be a supportive treatment in migraine treatment, with no serious adverse effects reported. This is an uncontrolled study with a small sample size.

Palamar et al. (2015) performed a prospective, randomized, placebo-controlled; double-blind pilot trial to compare the effectiveness of ultrasound-guided greater occipital nerve block (GONB) using bupivacaine 0.5% and placebo on clinical improvement in patients with refractory migraine without aura (MWOA). Thirty-two patients with a diagnosis of MWOA were randomly assigned to receive either GONB with local anesthetic (bupivacaine 0.5% 1.5 mL) or greater occipital nerve (GON) injection with normal saline (0.9% 1.5 mL). The treatment group consisted of 11 patients and the placebo group was comprised of 12 patients. The ultrasound-guided GONB was performed to accurately locate the nerve. Headache severity was assessed with the visual analogue scale (VAS) from 0 (no pain) to 10 (intense pain). In both groups, a decrease in headache intensity on the injection side was observed during the first post-injection week and continued until the second week. After the second week...
in the treatment group, the improvement continued and the VAS score was increased at the end of the fourth week. In the placebo group the VAS score increased and nearly reached the pre-injection levels after the second week. The decrease in the monthly average pain intensity score on the injected side was statistically significant in the treatment group, but not in the placebo group. The authors noted that ultrasound guided GONB with bupivacaine for the treatment of migraine patients is a safe, simple, and effective technique without severe adverse effects. This trial included a small sample with a short follow-up duration. Patients were followed for one month after the injection, so long-term effects of the injection have not been observed.

In a multicenter, double-blind, randomized placebo-controlled crossover trial, Inan et al. (2015) evaluated the safety and efficacy of unilateral GONB (greater occipital nerve block) in 84 patients with chronic migraine at 1, 2, and 3 month follow-ups. Patients were randomly assigned to either an intervention group (A) and received GONB with injections of 0.5% bupivacaine (n = 42) or a placebo group (B) receiving 2.5 mL saline (n = 42) once a week for 4 weeks. After 4 weeks, the study was unblinded and patients in the placebo group were crossed over to GONB with bupivacaine once per week for 8 weeks. Patients in the intervention group were followed for 4 weeks, and GONB was repeated with bupivacaine. After 1 month of treatment, the number of headache days had decreased from 16.9 ± 5.7 to 13.2 ± 6.7 in group A and from 18.1 ± 5.3 to 8.8 ± 4.8 in group B. The mean duration of headache (hours) had decreased from 25.9 ± 16.3 to 19.3 ± 11.5 in group A and from 24.2 ± 13.7 to 21.2 ± 13.4 in group B. The VAS score was significantly lower in the intervention group. After 2 months of treatment, when the placebo group received active treatment, the mean number of headache days decreased to 6.6 ± 4.7 in group A and to 8.4 ± 5.0 in group B. After 3 months, headache frequency had decreased significantly in group A (5.5 ± 4.0), and in group B (6.7 ± 5.2) but the difference between the groups was not significant. The mean duration of headache (hours) had decreased to 14.0 ± 10.4 in the group A, and to 15.1 ± 8.9 in group B. The difference was not significant between the groups. After 3 months of treatment, the hours had declined further to a mean of 10.0 ± 6.2 in group A, and 10.8 ± 5.9 in group B but again, the difference was not significant between the two groups. The mean VAS score improved in both the intervention and placebo groups with similar improvements in the two groups. The authors stated the evidence suggests that GONB with bupivacaine relieves migraine headache symptoms and reduces the frequency of the attacks compared with a placebo. This was confirmed when the placebo patients crossed over to active treatment and experienced significant symptom relief. The study is limited by its small sample size, short follow-up time, and short duration of the double-blind phase.

Gabrhelik et al. (2011) compared the efficacy of pulsed radiofrequency to the greater occipital nerve versus a greater occipital nerve block with a mixture of local anesthetic and steroid in the management of refractory cervicogenic headache. The study included 30 patients who were randomly allocated into two groups of fifteen. A greater occipital nerve block with steroid was utilized in group A, while a pulsed radiofrequency treatment was used in group B. At three months post therapy a significant decrease in Visual Analogue Scale was identified (3.2 points in group A, 3.3 points in group B). In group B, pain remained reduced even after 9 months when compared to pre-treatment scores. The consumption of analgesic medication was reduced significantly in both groups at three months and nine months. No serious complication was noted. The authors concluded that greater occipital nerve block is a safe, efficient technique in the management of cervicogenic headaches. According to the authors, the main limitation of this study is a small sample size.

In a randomized, double-blind, placebo-controlled trial, Naja et al. (2006a) evaluated the effectiveness of nerve stimulator-guided occipital nerve blockade in the treatment of cervicogenic headache. The reduction in analgesic consumption was the primary outcome measure. Fifty adult patients diagnosed with cervicogenic headache were randomly divided into two equal groups of 25 patients each. All patients in both groups received greater and lesser occipital blocks, whereas only 16 patients in each group received facial nerve blockade in association with the occipital blocks. The control group received injections of an equivalent volume of preservative-free normal saline. Pain was assessed using the visual analog scale (VAS) and the Total Pain Index (TPI). Forty-seven patients entered into the final analysis as three patients were lost to follow-up. Anesthetic block was effective in reducing the VAS and the TPI by approximately 50% from baseline values. Analgesic consumption, duration of headache and its frequency, nausea, vomiting, photophobia, phonophobia, decreased appetite, and limitations in functional activities were significantly less in block group compared to control group. The nerve stimulator-guided occipital nerve blockade significantly relieved cervicogenic headache and associated symptoms at two weeks following injection. This study is limited by a small sample size. Another major limitation of the study is the short duration of follow-up. The patients included in the study were followed for 2 weeks, so long-term outcome was not evaluated. The difficulty in blinding when numbness resulted in patients who received anesthetic blockade is another limitation of this study. In a follow-up trial, the same group evaluated 47 patients with cervicogenic headaches and found that 87% of the patients required more than one occipital nerve injection to achieve 6 months of pain relief.
Weibelt et al. (2010) evaluated the safety and efficacy of occipital nerve blocks (ONBs) used to treat cervicogenic chronic migraine (CCM) and identified variables predictive of a positive treatment response. A positive treatment outcome was defined as a 50% or greater reduction in headache days per month over the 30 days following treatment relative to the 30-day pre-treatment baseline. A total of 150 consecutive patients were treated with unilateral (37) or bilateral (113) ONBs. At the 1-month follow-up visit, 78 (52%) exhibited evidence of a positive treatment response according to the primary outcome variable, and 90 (60%) reported their headache disorder to be “better” (44; 29%) or “much better” (46; 30%). A total of 8 (5%) patients reported adverse events within the ensuing 72 hours, and 3 (2%) experienced adverse events that reversed spontaneously but required emergent evaluation and management. The investigators concluded that for suppression of CCM, ONBs may offer an attractive alternative to orally administered prophylactic therapy. This study lacked a control group and the data used for analyzing the primary outcome variable were partially dependent on patient recall. Both recall bias and placebo effect could have inflated the response rate.

Na et al. (2010) evaluated the efficacy of ultrasonic Doppler flowmeter-guided occipital nerve block in 26 patients experiencing headache in the occipital region in a randomized, prospective, placebo-controlled study. Patients received a greater occipital nerve block performed either under ultrasonic Doppler flowmeter guidance using 1% lidocaine or the traditional method. Sensory examination findings in the occipital region were evaluated. The complete block rate of greater occipital nerve blockade in the Doppler group was significantly higher than in the control group respectively (76.9% vs. 30.8%). Only one patient in the control group had a complication (minimal bleeding). The authors concluded that ultrasonic Doppler flowmeter-guided occipital nerve block may be a useful method for patients suffering headache in the occipital region. These findings require confirmation in a larger study.

Voigt and Murphy (2015) conducted a systematic literature review of the available evidence regarding the use of occipital nerve blocks (ONBs) for the management of acute headaches, and then determined its potential for use in the emergency care setting. Techniques, medication selection, adverse reactions, frequency of use, candidates, and measures that can help improve safety were reviewed in order to better evaluate the usefulness of this tool in emergency care. The authors utilized the U.S. Preventive Services Task Force grading of evidence definitions and created the following grades based on available research for the use of ONBs in the treatment of various types of headaches: Cluster headache B (Moderate), Cervicogenic headache B (Moderate), Migraine headache C (Low), Tension-type headache I (insufficient evidence), Hemicrania continua I (insufficient evidence), and Chronic daily headache C (Low). The authors concluded that current evidence supports that ONBs can be delivered safely in an outpatient setting by providers who have been trained in and have practiced this procedure. According to the authors, current evidence supports that ONBs can be useful in treating acute headaches in an emergency care setting although additional research is needed.

Ashkenazi et al. (2010) performed a systematic review of peripheral nerve blocks (PNBs) and trigger point injections (TPIs) for headache treatment. The authors found few controlled studies on the efficacy of PNBs for headaches, and virtually none on the use of TPIs for headaches. The most widely examined procedure in this setting was greater occipital nerve block, with the majority of studies being small and non-controlled. The techniques, as well as the type and doses of local anesthetics used for nerve blockade, varied greatly among studies. The specific conditions treated also varied, and included both primary (e.g., migraine, cluster headache) and secondary (e.g., cervicogenic, posttraumatic) headache disorders. According to the authors, results for PNBs were generally positive, but should be taken with reservation given the methodological limitations of the available studies. These limitations included small patient populations, retrospective, non-controlled designs, and heterogeneous groups of patients. The authors concluded that there is a need to perform more rigorous clinical trials to clarify the role of PNBs and TPIs in the management of various headache disorders, and to aim at standardizing the techniques used for the various procedures in this setting.

Leroux et al. (2011) conducted a randomized, double-blind, placebo-controlled trial that included adults with more than two cluster headache attacks per day. Forty-three patients were randomly allocated to receive three suboccipital injections (48-72 hours apart) of cortivazol or placebo, as add-on treatment to oral verapamil in patients with episodic cluster headache and as add-on prophylaxis for those with chronic cluster headache. Injections were done by physicians who were aware of treatment allocation, but patients and the evaluating physician were masked to allocation. Twenty of 21 patients who received cortivazol had a mean of two or fewer daily attacks after injections compared with 12 of 22 controls. Patients who received cortivazol also had fewer attacks in the first 15 days of study than did controls. No serious adverse events were noted. Thirty-two (74%) of 43 patients had other adverse events (18 of 21 patients who received cortivazol and 14 of 22 controls). The most common adverse events were injection-site neck pain and non-cluster headache. According to the authors, suboccipital cortivazol injections can
relieve cluster headaches rapidly in patients having frequent daily attacks, irrespective of type (chronic or episodic). The authors stated that safety and tolerability need to be confirmed in larger studies.

Lambru et al. (2014) prospectively assessed the efficacy and consistency of response to greater occipital nerve blockade (GONB) in a series of 83 chronic cluster headache (CCH) patients. After the first GONB, a positive response was observed in 47 (57%) patients: 35 (42%) were rendered pain free, 12 (15%) had a partial benefit and one patient obtained < 50% improvement. The duration of a positive response lasted a median of 21 days (range 7-504 days). There was a transient worsening of condition in 6% of patients. The overall rate and average duration of response remained consistent after the second [n = 37; 31 responders (84%); median duration 21 days], third [n = 28; 20 responders (71%); median duration 25 days] and fourth [n = 14; 10 responders (71%); median duration 23 days] injections. The authors concluded that GONB seems to be an efficacious treatment with reproducible effects in CCH patients. According to the authors, when performed three times monthly, GONB may have a useful role in the management of CCH. The lack of a control group limits the validity of the results of this study.

Gantenbein et al. (2012) retrospectively analyzed the efficacy and safety of 121 GON injections in 60 patients with episodic or chronic cluster headache over a period of 4 years. Almost 80% of the infiltrations were at least partially effective (reduction of attack frequency, duration or severity) and 45% resulted in a complete response (no further attacks). The effect was maintained for 3.5 weeks on average in chronic cluster headache. In episodic cluster headache, the effect lasted for most of the bout. In 18 infiltrations, transient side effects were reported, such as local pain, steroid effects (facial edema, sleeping disorders, acne), bradycardia or syncope. The authors concluded that GON infiltration is a valuable and safe option in the clinical setting to treat patients suffering from cluster headache, especially for the episodic form of the disorder. This is an uncontrolled study with a small sample size.

Saracco et al. (2010) assessed whether adding triamcinolone to local anesthetics increased the efficacy of greater occipital nerve block (GONB) and trigger point injections (TPIs) for chronic migraine. Thirty-seven patients with chronic migraine were randomized to receive GONB and TPIs using lidocaine 2% and bupivacaine 0.5% plus either saline (group A) or triamcinolone 40 mg (group B). Patients documented headache and severity of associated symptoms for 4 weeks after injection. Changes in symptom severity were compared between the two groups. Twenty minutes after injection, mean headache severity decreased by 3.2 points in group A and by 3.1 points in group B. Mean neck pain severity decreased by 1.5 points in group A and by 1.7 points in group B. Mean duration of being headache-free was 2.7 +/- 3.8 days in group A and 1.0 +/- 1.1 days in group B. None of the outcome measures differed significantly between the two groups. According to the investigators, adding triamcinolone to local anesthetic when performing GONB and TPIs was not associated with improved outcome in the sample of patients with chronic migraine. In both groups, the procedure resulted in significant and rapid relief of headache, neck pain, and photophobia. The study is limited by a small sample size and lack of a control therapy.

Naja et al. (2009) conducted a prospective, randomized, single-blinded comparison between bilateral occipital blockade and conventional expectant therapy in adults suffering from postdural puncture headache (PDPH). Fifty adult patients diagnosed with PDPH were randomly divided into two equal groups of 25 each. All patients in the block group received greater and lesser occipital nerve blocks, whereas the control group received adequate hydration, complete bed rest, and analgesics. Forty-seven patients entered into the final analysis as three patients withdrew from study. Complete pain relief was achieved in 68.4% of block patients after 1 to 2 blocks, with 31.6% ultimately receiving up to 4 blocks. Visual analog scales were significantly lower in the block group, and the block group consumed significantly less analgesics in the follow-up period compared with control group. Block patients had significantly shorter hospital stays and sick leave periods. The investigators concluded that occipital nerve blockade is superior to expectant conservative therapy in the treatment of patients suffering from PDPH. These findings require confirmation in a larger study.

Tobin et al. (2009) conducted a chart review of 108 occipital nerve blocks (ONBs) to explore the effect of symptomatic medication overuse (SMO) and ONB efficacy. ONB failed in 22% of injections overall. Of the other 78%, the mean decrease in head pain was 83%, and the benefit lasted a mean of 6.6 weeks. Failure rate without SMO was 16% overall, and with SMO was 44% overall. In those who did respond, overall magnitude and duration of response did not differ between those with and those without SMO. Without SMO, ONB failure rate was 0% for postconcussive syndrome, 14% for occipital neuralgia, 11% for non-intractable migraine, and 39% for intractable migraine. With SMO, failure rate increased by 24% in occipital neuralgia, by 36% for all migraine, and by 52% for non-intractable migraine. The investigators concluded that SMO tripled the risk of ONB failure, possibly because medication overuse headache does not respond to ONB. This study lacked a control group.
Dilli et al. (2014) evaluated the efficacy of ONB with local anesthetic and corticosteroid for the preventive treatment of migraine. Patients between 18 and 75 years old with International Classification of Headache Disorders (ICHD)-defined episodic (> 1 attack per week) or chronic migraine were randomized to receive either 2.5 ml 0.5% bupivacaine plus 0.5 ml (20 mg) methylprednisolone over the ipsilateral (unilateral headache) or bilateral (bilateral headache) occipital nerve (ON) or 2.75 ml normal saline plus 0.25 ml 1% lidocaine without epinephrine (placebo). Patients completed a one-month headache diary prior to and after the double-blind injection. The primary outcome measure was defined as a 50% or greater reduction in the frequency of days with moderate or severe migraine headache in the four-week post-injection compared to the four-week pre-injection baseline period. Thirty-four patients received active and 35 patients received placebo treatment. Because of missing data, the full analysis of 35 patients in the active and 30 patients in the placebo group was analyzed for efficacy. In the active and placebo groups respectively, the mean frequency of at least moderate (mean 9.8 versus 9.5) and severe (3.6 versus 4.3) migraine days and acute medication days (7.9 versus 10.0) were not substantially different at baseline. The percentage of patients with at least a 50% reduction in the frequency of moderate or severe headache days was 30% for both groups. The authors concluded that greater ONB does not reduce the frequency of moderate to severe migraine days in patients with episodic or chronic migraine compared to placebo.

Kashipazha et al. (2014) conducted a randomized double-blinded controlled trial to evaluate the therapeutic efficacy of greater occipital nerve block (GONB) on 48 patients suffering from migraine headaches. A syringe containing 1.0 mL of lidocaine 2%, 0.5 mL of either saline (control group, N = 24) or triamcinolone 0.5 mL (intervention group, N = 24) was prepared for each patient. Patients were assessed prior to the injection, and also 2 weeks, 1 month, and 2 months thereafter for severity and frequency of pain, times to use analgesics and any appeared side effects. No significant differences were revealed in pain severity, pain frequency, and analgesics use between the two groups at the four study time points including at baseline, and 2, 4, and 8 weeks after the intervention. However, in both groups, the indices of pain severity, pain frequency, and analgesics use were significantly reduced at the three time points after the intervention compared with before the intervention. The authors concluded that GONB with triamcinolone in combination with lidocaine or normal saline with lidocaine results in reducing pain severity and frequency as well as use of analgesics up to two months after the intervention; however, any difference attributed to the drug regimens by assessing of the trend of pain characteristics changes. These findings require confirmation in a larger study.

Other studies have been performed that indicate that greater occipital nerve blocks may be an effective treatment for patients with migraine postconcussive, or other headaches; however, these studies had small sample sizes or did not have control groups (Lauretti, 2014; Niraj, 2014; Govindappagari, 2014; Seeger, 2014; Guerrero, 2012; Young, 2008; Akin, 2008). The American Headache Society Special Interest Section for peripheral nerve blocks (PNBs) and other Interventional Procedures (AHS-IPS) developed a narrative review describing a standardized methodology for the performance of PNBs in the treatment of headache disorders. PNBs described included greater occipital, lesser occipital, supratrochlear, supraorbital, and auriculotemporal injections. The indications for PNB may include select primary headache disorders, secondary headache disorders, and cranial neuralgias. According to the authors, there is a paucity of evidence from controlled studies for the use of PNBs in the treatment of primary and secondary headache disorders, with the exception of greater occipital nerve blockade for cluster headaches. The AHS-IPS indicated that further research may result in the revision of these recommendations to improve the outcome and safety of this treatment modality for headache (Blumenfeld et al. 2013).

The National Comprehensive Cancer Network (NCCN) practice guidelines (2020) for adult cancer pain indicate that interventional therapies that can be useful in the relief of cancer pain include nerve blocks and RF ablation. This recommendation is based on category 2A level of evidence (based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate).

**Surgical Treatment of Occipital Neuralgia or Cervicogenic Headache**

A number of different surgical procedures such as dorsal nerve root section, occipital neurectomy, partial posterior rhizotomy, cervical spine disc excision with fusion, and surgical nerve release have been studied for the treatment of occipital neuralgia and cervicogenic headache.

A systematic review and meta-analysis to evaluate the proportion of migraine patients reporting elimination of migraine headache (MH) after migraine trigger site surgery and whether surgery compared to sham or no surgery is more effective in the elimination of MH was conducted by Vincent et al. (2019). A total number of 627 patients with a diagnosis of migraine in compliance with the classification of the International Headache Society were included. The treatment consisted of one or more surgical procedures involving the extracranial nerves and/or arteries with outcome data available at minimum 6 months. A
proportion of 0.38 of patients (random effects model, 95% CI [0.30–0.46]) experienced elimination of migraine headaches at 6–12 months follow-up. Using data from three randomized controlled trials, the calculated odds ratio for 90–100% elimination of migraine headaches is 21.46 (random effects model, 95% CI [5.64–81.58]) for patients receiving migraine surgery compared to sham or no surgery. The authors reported that migraine surgery leads to elimination of migraine headaches in 38% of migraine patients. However, more elaborate randomized trials are needed with transparent reporting of patient selection, medication use, and surgical procedures and implementing detailed and longer follow-up times.

Gande et al. (2016) performed a retrospective chart review of 75 occipital neuralgia (ON) patients who underwent cervical dorsal root rhizotomy (CDR). Fifty-five patients were included who met the International Headache Society’s (IHS) diagnostic criteria for ON, responded to CT-guided nerve blocks at the C-2 dorsal nerve root, and had at least one follow-up visit. Telephone interviews were additionally used to obtain data on patient satisfaction. The average follow-up was 67 months (range 5-150). Etiologies of ON included the following: idiopathic (44%), posttraumatic (27%), postsurgical (22%), post-cerebrovascular accident (4%), postherpetic (2%), and postviral (2%). At last follow-up, 35 patients (64%) reported full pain relief, 11 (20%) partial relief, and 7 (16%) no pain relief. The extent of pain relief after CDR was not significantly associated with ON etiology. Of 37 patients whose satisfaction-related data were obtained, 25 (68%) reported willingness to undergo repeat surgery for similar pain relief, while 11 (30%) reported no such willingness; a single patient (2%) did not answer this question. Twenty-one individuals (57%) reported that their activity level/functional state improved after surgery, 5 (13%) reported a decline, and 11 (30%) reported no difference. The most common acute postoperative complications were infections in 9% (n = 5) and CSF leaks in 5% (n = 3); chronic complications included neck pain/stiffness in 16% (n = 9) and upper-extremity symptoms in 5% (n = 3) such as trapezius weakness, shoulder pain, and arm paresthesias. The authors concluded that cervical dorsal root rhizotomy provides an efficacious means for pain relief in patients with medically refractory ON. In the appropriately selected patient, it may lead to optimal outcomes with a relatively low risk of complications. The study is limited by its retrospective observations.

Excision of intervertebral discs from the cervical spine with interbody fusion was evaluated in two prospective case series by the same authors. In patients with bilateral cervicogenic headache (n = 28), 64% reported relief of pain after surgery, and the mean duration of improvement was 22.7 months. In 36% of patients, immediate pain reduction was followed by recurrences starting at 2 months after surgery (Jansen and Sjaastad, 2006). In patients with unilateral cervicogenic headache, these same authors reported that all patients were generally pain free during the 1- to 3-month period when the patients wore cervical collars restricting movement, but only 5 out of 32 patients remained pain free 3 years after surgery. The mean duration of improvement was 14.8 months (range, 1 to 58 months) (Jansen and Sjaastad, 2007). In another study, Jansen (2008) summarized the results of cervical disc removal in 60 patients with long lasting severe unilateral (n = 32) or bilateral (n = 28) cervicogenic headache unresponsive to other treatment options. Sixty-three per cent of the unilateral and 64% of the bilateral cases had long lasting pain freedom or improvement. After secondary deterioration (in 37% of patients with unilateral and in 36% with bilateral CEH) and further treatments, the final mean improvement was 73% and 66%, respectively. The mean observation time was short (19.8 to 25.5 months). These conclusions are limited by the small sample size in the reported studies.

Choi et al. (2015) performed a retrospective analysis in 68 patients with medically refractory occipital neuralgia who underwent C2 ganglion decompression for intractable occipital neuralgia. All patients had failed to respond to conservative management, including combination pharmacotherapy, steroids or a Botox injection, acupuncture, and physical therapy. The average duration of symptoms prior to surgery was 13.7 years. Pain was assessed before C2 anesthetic blockade and after 1 year and 5 years following surgery, and therapeutic success was defined as pain relief by at least 50% without ongoing medication. All the patients experienced temporary pain relief after surgical decompression; however, two patients experienced recurrence within a week after the operation. At the 1-year follow-up, 57 patients (83.8%) had more than 50% pain relief. Of 57 patients, 12 experienced an excellent result (no headache) and 45 had a good result (headache relief more than 50%). The remaining 11 patients experienced recurrence of symptoms as a poor result (headache relief less than 50%), even if they experienced adequate pain relief after the operation. At the 5-year follow-up, 55 patients had excellent or good results and 13 patients with poor results were identified. The long-term outcome after 5 years was only slightly less than the 1-year outcome; 47 of the 68 patients (69.1%) obtained therapeutic success. Longer duration of headache and presence of retro-orbital/frontal radiation were significantly associated with poor prognosis. The authors stated that this current study demonstrated that C2 ganglion decompression provided durable, adequate pain relief with minimal complications in patients suffering from intractable occipital neuralgia. Further study is required to manage the pain recurrence associated with longstanding nerve injury. The study is limited by its retrospective observations.

In a prospective study, Diener et al. (2007) investigated whether cervical disc prolapse can cause cervicogenic headache. The study included 50 patients with cervical disc prolapse who were prospectively followed for 3 months. Data regarding headache...
and neck pain were collected prior to and 7 and 90 days after surgery for the disc prolapse. Fifty patients with lumbar disc prolapse, matched for age and sex, undergoing surgery were recruited as controls. Twelve of 50 patients with cervical disc prolapse reported new headache and neck pain. Seven patients (58%) fulfilled the 2004 International Headache Society criteria for cervicogenic headache. One week after surgery, 8/12 patients with cervical disc prolapse and headache reported to be pain free. One patient was improved and three were unchanged. Three months after cervical prolapse surgery, seven patients were pain free, three improved and two unchanged. According to the authors, this prospective study shows an association of low cervical prolapse with cervicogenic headache: headache and neck pain improves or disappears in 80% of patients after surgery for the cervical disc prolapse. These findings require confirmation in a larger study.

A retrospective chart review was conducted to identify 206 consecutive patients undergoing neurolysis of the greater or, less commonly, excision of the greater and/or lesser occipital nerves. Of 206 patients, 190 underwent greater occipital nerve neurolysis (171 bilateral). Twelve patients underwent greater and lesser occipital nerve excision, whereas four underwent lesser occipital nerve excision alone. The investigators found that 80.5% of patients experienced at least 50% pain relief and 43.4% of patients experienced complete relief of headache. Minimum duration of follow-up was 12 months (Ducic et al., 2009). Interpretation of these findings is limited due to the retrospective design of the study.

In a retrospective review, Pisapia et al. (2012) evaluated the effectiveness of C2 nerve root decompression and C2 dorsal root ganglionectomy for intractable occipital neuralgia (ON) and C2 ganglionectomy after pain recurrence following initial decompression. Of 43 patients, 29 were available for follow-up after C2 nerve root decompression (n = 11), C2 dorsal root ganglionectomy (n = 10), or decompression followed by ganglionectomy (n = 8). Telephone contact supplemented chart review and patients rated their preoperative and postoperative pain on a 10-point numeric scale. Overall, 19 of 29 patients (66%) experienced a good or excellent outcome at most recent follow-up. Among the 19 patients who completed the telephone questionnaire (mean follow-up 5.6 years), patients undergoing decompression, ganglionectomy, or decompression followed by ganglionectomy experienced similar outcomes, with mean pain reduction ratings of 5, 4.5, and 5.7, respectively. Of 19 telephone responders, 13 (68%) rated overall operative results as very good or satisfactory. According to the authors, most patients experienced favorable postoperative pain relief. The authors stated that for patients with pain recurrence after C2 decompression, salvage C2 ganglionectomy is a viable surgical option and should be offered with the potential for complete pain relief and improved quality of life. The moderate rate of follow-up (67%) may have skewed the results of this study.

In a retrospective chart review, Acar et al. (2008) evaluated 20 patients who underwent C2 and/or C3 ganglionectomies for intractable occipital pain. All patients reported preoperative pain relief following cervical nerve blocks. The mean follow-up was 42.5 months. Average visual analog scale scores were 9.4 preoperatively and 2.6 immediately after procedure. Ninety-five percent of patients reported short-term pain relief (< 3 months). In 13 patients (65%), pain returned after an average of 12 months (C2 ganglionectomy) and 8.4 months (C3 ganglionectomy). Long-term results were excellent, moderate and poor in 20, 40 and 40% of patients, respectively. The investigators concluded that cervical ganglionectomy offers relief to a majority of patients, immediately after procedure, but the effect is short lived. Nerve blocks are helpful in predicting short-term success, but a positive block result does not necessarily predict long-term benefit and therefore cannot justify surgery by itself.

Li et al. (2012) evaluated the clinical effect of micro-surgical decompression of the greater occipital nerve for greater occipital neuralgia (GON) in 76 patients. The mean follow up duration was 20 months (range 7-52 months). The headache symptoms of 68 patients (89.5%) were completely resolved, and another 5 patients (6.6%) were significantly relieved without the need for any further medical treatment. Three patients (3.9%) experienced recurrence of the disorder. All patients experienced hypoesthesia of the innervated area of the great occipital nerve. They recovered gradually within 1 to 6 months after surgery. According to the authors, micro-surgical decompression is a promising therapy for GON given its low risk and high effectiveness. The significance of this study is limited by small sample size and short follow-up period. Further controlled prospective studies are needed to evaluate the exact effects and long-term outcomes of this treatment method.

**Nerve Decompression and Occipital Neurectomy for Headaches**

A retrospective review of clinical records was conducted by Blake et al. (2019). Inclusion criteria were evidence of chronic occipital headache with and without migrainous features and tenderness of neck muscles, occipital allodynia, and inadequate response to prophylactic drugs. Surgical decompression of the greater and lesser occipital nerves provided complete and extended (3-6 years) relief of new daily persistent headache in case 3 (46 year old female), and of chronic post-traumatic headache in cases 4 and 6 (35 and 30 year old females, respectively), partial relief of chronic headache/migraine in cases 1 and 2 (41 year old female and 36 year old male), and no relief of episodic (cases 3 and 4) or chronic migraine (case 5, 52 year old male), or chronic tension-type headache (case 7, 31 year old male). The authors concluded that as a case series, this study
Jose et al. (2018) performed a study to evaluate the effectiveness of greater occipital nerve decompression for the management of occipital neuralgia. Eleven patients with occipital neuralgia were enrolled in the study. All underwent surgical decompression of the greater occipital nerve at the level of semispinals capitis and trapezial tunnel. A pre and postoperative questionnaire was used to compare the severity of pain and number of pain episodes/month. Mean pain episodes reported by patients before surgery were $17.1 \pm 5.63$ episodes per month. This reduced to $4.1 \pm 3.51$ episodes per month postsurgery. The mean intensity of pain also reduced from a preoperative $7.18 \pm 1.33$ to a postoperative of $1.73 \pm 1.95$. Three patients reported complete elimination of pain after surgery and 6 patients reported significant relief of their symptoms. Two patients failed to notice any significant improvement. The mean follow-up period was $12.45 \pm 1.29$ months. The authors concluded that surgical decompression of the greater occipital nerve is a simple and viable treatment modality for the management of occipital neuralgia. Limitations include non-randomization and small sample size.

Ambrosini and Schoenen (2016) performed a meta-analysis of studies assessing (minimally) invasive interventions targeting pericranial nerves that could be effective in refractory patients. These included nerve blocks/infiltrations, the percutaneous implantation of neurostimulators and surgical decompression procedures. The authors concluded that the clinical implications for these treatments are as follows:

- Suboccipital infiltrations (or greater occipital nerve blocks) are effective, evidence-based, safe and inexpensive treatments for short-term prophylaxis in cluster headache patients; while evidence for such an effect is weak in migraine.
- Percutaneous occipital nerve stimulation (ONS) has long-term efficacy in refractory chronic cluster headache, but it has frequent adverse effects, and a sham-controlled trial is not yet available.
- Surgical decompression of pericranial nerves in migraine patients was reported to be superior to sham surgery in one study, and most case series are non-controlled and published by the same group. Further better-designed RCTs are needed before surgical decompressions can be recommended in the treatment of selected migraine patients.

Guyuron et al. (2011) assessed the long-term efficacy of surgical deactivation of migraine headache trigger sites. One hundred twenty-five volunteers were randomly assigned to the treatment (n = 100) or control group (n = 25) after examination by the team neurologist to ensure a diagnosis of migraine headache. Patients were asked to complete the Medical Outcomes Study 36-Item Short Form Health Survey, Migraine-Specific Quality of Life, and Migraine Disability Assessment questionnaires before treatment and at 12- and 60-month postoperative follow-up. The treatment group received botulinum toxin to confirm the trigger sites; controls received saline injections. Treated patients underwent surgical deactivation of trigger site(s). Eighty-nine of 100 patients in the treatment group underwent surgery, and 79 were followed for 5 years. Ten patients underwent deactivation of additional (different) trigger sites during the follow-up period and were not included in the data analysis. The final outcome with or without inclusion of these 10 patients was not statistically different. Sixty-one (88 percent) of 69 patients experienced a positive response to the surgery after 5 years. Twenty (29 percent) reported complete elimination of migraine headache, 41 (59 percent) noticed a significant decrease, and eight (12 percent) experienced no significant change. When compared with the baseline values, all measured variables at 60 months improved significantly. Based on the 5-year follow-up data, the authors concluded that there is strong evidence that surgical manipulation of one or more migraine trigger sites can successfully eliminate or reduce the frequency, duration, and intensity of migraine headache in a lasting manner. This study is of limited significance because no statistical comparisons were made at the 5 year follow-up and patient-reported data may have introduced recall bias in the study.

A randomized trial of patients with medication-refractory, but BT-responsive, migraine headaches compared the removal of the glabellar muscles (n = 19), removal of the zygomaticotemporal branch of the trigeminal nerve (n = 19), or greater occipital neurectomy (n = 11) with sham-control patients (n = 26) who underwent only exposure at one of the sites. At 1-year follow-up, complete resolution of headaches was found in 57.1% and significant improvement in 83.7% of patients undergoing actual surgery, and significant improvement was found compared with baseline values in all migraine headache measures. In the sham surgery group, 57.7% of patients reported at least 50% reduction in migraine headache. The difference between experimental and control groups was statistically significant (Guyuron et al., 2009). These findings require confirmation in a larger study.

Ducic et al. (2014) systematically compared the outcomes of different types of interventional procedures offered for the treatment of headaches and targeted toward peripheral nerves based on available published literature. The objective of this study was to systematically review the literature to compare the published outcomes and effectiveness of peripheral nerve...
surgery, radiofrequency (RF) therapy, and peripheral nerve stimulators for chronic headaches, migraines, and occipital neuralgia. A total of 26 studies met the inclusion criteria. Of these, 14 articles studied nerve decompression, 9 studied peripheral nerve stimulation, and 3 studied RF intervention. When study populations and results were pooled, a total of 1253 patients had undergone nerve decompression with an 86% success rate. The authors concluded that of the 3 most commonly encountered interventional procedures for chronic headaches, peripheral nerve surgery via decompression of involved peripheral nerves has been the best-studied modality in terms of total number of studies, level of evidence of published studies, and length of follow-up. Reported success rates for nerve decompression or excision tend to be higher than those for peripheral nerve stimulation or for RF, although poor study quantity and quality prohibit an accurate comparative analysis. Although peripheral nerve surgery seems to be the interventional treatment modality that is currently best supported by the literature, better controlled and normalized high-quality studies will help to better define the specific roles for each type of intervention.

In an effort to draw attention to tests and procedures associated with low-value care in headache medicine, the American Headache Society (AHS) joined the Choosing Wisely initiative of the American Board of Internal Medicine Foundation. One of the recommendations approved by the Choosing Wisely task force of the AHS was do not recommend surgical deactivation of migraine trigger points outside of a clinical trial (Loder et al. 2013).

Radiofrequency Ablation

Lee et al. (2020) performed a retrospective chart review to evaluate the efficacy and complications of C2 dorsal root ganglion (DRG) pulsed radiofrequency ablation (RFA) for cervicogenic headache (CEH) and to identify factors related to the outcome of the procedure. Electronic medical records of consecutive patients who underwent C2 DRG block for CEH from January 2012 to May 2018 at a pain center were reviewed. Consequent C2 DRG pulsed RFA was performed for patients in whom the headache recurred after an initial period of relief 24 hours after the C2 DRG block. A successful outcome was defined as at least 50% pain relief at 6 months after C2 DRG pulsed RFA. Fluoroscopy-guided C2 DRG block was performed in 114 patients. Forty-five patients received C2 DRG pulsed RFA and 40.0% among them (18/45, success group) had ≥50% pain relief after 6 months. There were no post-procedure complications throughout the study period. More patients in the success group than in the failure group had a definite positive response (≥50% pain relief) to a previous C2 DRG block (P<.001). The authors concluded that C2 DRG pulsed RFA may be an effective treatment for patients with CEH, particularly for patients who have previously experienced definite pain reduction after C2 DRG block. The limitations of the study design and small number of patients preclude firm conclusions.

Grandhi et al. (2018) performed a systematic review to examine the use of radiofrequency ablation (RFA) and pulse radiofrequency (PRF) for the management of cervicogenic headache (CHA). A review of the literature was conducted and 10 studies met inclusion for review. The authors concluded that RFA and PRFA provided very limited benefit in the management of CHA and there is no high-quality RCT and/or strong non-RCTs to support the use of these techniques, despite numerous case reports that had demonstrated benefit.

Luo et al. (2018) prospectively investigated the long-term effects of ultrasound-guided percutaneous pulsed radiofrequency in the treatment of 22 refractory idiopathic supraorbital neuralgia patients. A reduction in the verbal pain numeric rating scale score of more than 50% was used as the standard of effectiveness. The effectiveness rates at different time points within 2 years were calculated. After a single pulsed radiofrequency treatment, the effectiveness rate at 1 and 3 months was 77 %, and the rates at 6 months, 1 year, and 2 years were 73 %, 64 %, and 50 %, respectively. Twenty-three percent of patients experienced mild upper eyelid ecchymosis that gradually disappeared after approximately 2 weeks. The authors concluded that the study demonstrated that for patients with refractory idiopathic supraorbital neuralgia, percutaneous pulsed radiofrequency may be a safe and effective treatment choice. The findings of this study need to be validated by well-designed studies.

A 2018 ECRI Health Technology Assessment on radiofrequency denervation for treating cervical facet joint pain found inconclusive evidence for the effectiveness of cervical facet (CF) joint RFD for treating cervicogenic headaches. The evidence has major limitations, and blinded randomized controlled trials (RCTs) are needed to confirm results and compare RFD with other treatments (ECRI, 2018).

Nagar et al. (2015) conducted a systematic review to investigate the clinical utility of radiofrequency (RF) neurotomy, and pulsed RF (PRF) ablation for the management of cervicogenic headache (CHA). The review included relevant literature identified through searches of PubMed, Cochrane, Clinical trials, U.S. National Guideline Clearinghouse and EMBASE from...
1960 to January 2014. The focus was on randomized trials and case-control, prospective, cohort, and cross-sectional studies with participants suffering from CHA who had failed conservative management. A study was judged to be positive if the interventions provided headache relief and improved quality of life. There were 5 non-randomized trials among them 4/5 were of moderate quality, 3/5 showed RF ablation and 1/5 showed PRF as an effective intervention for cervicogenic headache. There were 4 randomized trials among them 2/4 were of high quality, 3/4 investigated RF ablation as an intervention for CHA, and 1/4 investigated PRF ablation as an intervention for CHA. None of the randomized studies showed strong evidence for RF and PRF ablation as an effective intervention for CHA. There were 2 RCTs which did not show significant benefits with RFA. There is limited evidence for RF and pulsed RFA therapies for management of CHA. Evidence is insufficient to assess the effects on the health outcomes because of the limited number of studies or the low power of the studies, unexplained inconsistency between RCTs, flaws in trial design, gaps in the chain of evidence, and lack of detailed information on desired health outcomes.

Manolitsis and Elahi (2014) conducted an evidence-based review of the current literature concerning the use of pulsed radiofrequency (PRF) for occipital neuralgia. The authors found that a total of 3 clinical studies and one case report investigating the use of PRF for occipital neuralgia have been published worldwide. Statistically significant improvements in pain, quality of life, and adjuvant pain medication usage have been demonstrated. According to the authors the evidence limitations include lack of randomized control trials, small study sample sizes, an absence of diagnostic block imaging guidance, and the use of outcome measures that are inherently subjective, limiting objectivity and introducing an unquantifiable degree of bias. The authors concluded that clinical studies to date examining the efficacy of PRF as a treatment for occipital neuralgia have yielded promising results, demonstrating sustained improvement in pain, quality of life, and adjuvant pain medication usage. The authors stated that despite these encouraging clinical studies, conclusive evidence in support of PRF as an interventional treatment option for occipital neuralgia awaits to be seen.

Ducic et al. (2013) systematically compared the outcomes of different types of interventional procedures offered for the treatment of headaches and targeted toward peripheral nerves based on available published literature. The objective of this study was to systematically review the literature to compare the published outcomes and effectiveness of peripheral nerve surgery, radiofrequency (RF) therapy, and peripheral nerve stimulators for chronic headaches, migraines, and occipital neuralgia. A total of 26 studies met the inclusion criteria. Of these, 14 articles studied nerve decompression, 9 studied peripheral nerve stimulation, and 3 studied RF intervention. When study populations and results were pooled, a total of 1253 patients had undergone nerve decompression with an 86% success rate, 184 patients were treated by nerve stimulation with a 68% success rate, and 131 patients were treated by RF with a 55% success rate. The authors concluded that although peripheral nerve surgery seems to be the interventional treatment modality that is currently best supported by the literature, better controlled and normalized high-quality studies will help to better define the specific roles for each type of intervention.

Fang et al. (2016) conducted a study to evaluate the efficacy and safety of a non-ablative computerized tomography-guided pulsed radiofrequency treatment of sphenopalatine ganglion in patients with refractory cluster headaches. Sixteen consecutive cluster headache patients who failed to respond to conservative therapy treated with pulsed radiofrequency treatment (PRFT) of sphenopalatine ganglion were analyzed. Eleven of 13 episodic cluster headaches (ECH) patients (85%) and one of three chronic cluster headaches (CCH) patients (33%) were completely relieved of the headache. Two ECH patients and two CCH patients showed no pain relief following the treatment. The mean time following PRFT for partial pain relief was 1.3 days (ranging from 1 to 3 days) and the mean time following PRFT for complete pain relief was 6.3 days (ranging from 1 to 20 days). All patients enrolled in this study showed no treatment-related side effects or complications. The authors concluded that patients with refractory episodic cluster headaches were quickly, effectively and safely relieved from the cluster period after computerized tomography-guided pulsed radiofrequency treatment of sphenopalatine ganglion, suggesting that it may be a therapeutic option if conservative treatments fail. Large sample sizes and long-term follow-up research will be useful to evaluate the efficacy of PRFT in CCH patients.

Vanelderen et al. (2010) reported on the results of a prospective trial with 6 months of follow-up in which pulsed radiofrequency treatment of the greater and/or lesser occipital nerve was used to treat occipital neuralgia in 19 patients. Patients presenting with clinical findings suggestive of occipital neuralgia and a positive test block of the occipital nerves with 2 mL of local anesthetic underwent a pulsed radiofrequency procedure of the culprit nerves. Approximately 52.6% of patients reported a score of 6 (pain improved substantially) or higher on the Likert scale after 6 months. No complications were reported. The investigators concluded that pulsed radiofrequency treatment of the greater and/or lesser occipital nerve is a promising treatment of occipital neuralgia. This study warrants further placebo-controlled trials.
Huang et al. (2012) conducted a retrospective data analysis to evaluate the use of pulsed radiofrequency (PRF) for occipital neuralgia (ON) in 102 patients. Fifty-two (51%) patients experienced ≥50% pain relief and satisfaction with treatment lasting at least 3 months. Variables associated with a positive outcome included a traumatic inciting event, lower diagnostic block volumes, and employment of multiple rounds of PRF. Factors correlating with treatment failure included extension of pain anterior to the scalp apex and ongoing secondary gain issues. The authors concluded that PRF may provide intermediate-term benefit for ON in a significant proportion of refractory cases. The authors stated that careful attention to selection criteria and treatment parameters may further improve treatment outcomes. The significance of these findings is limited due to the retrospective design of the study and short follow-up time.

Neurostimulation or Electrical Stimulation for Headaches/Occipital Neuralgia

Aibar-Duran et al. (2020) describe two prospective cohorts of patients with refractory cluster headache (CH) treated with occipital nerve stimulation (ONS) and deep brain stimulation (DBS) and compare preoperative to postoperative status at 6 and 12 months after the surgery and at final follow-up. Efficacy analysis using objective and subjective variables is reported, as well as medication reduction and complications. The ONS group consisted of 13 men and 4 women. The median number of attacks per week (NAw) before surgery was 28, and the median follow-up duration was 48 months. The DBS group comprised 5 men and 2 women. The median NAw before surgery was 56, and the median follow-up was 36 months. The NAw and visual analog scale score were significantly reduced for the ONS and DBS groups after surgery. However, while all the patients from the DBS group were considered responders at final follow-up, with more than 85% being satisfied with the treatment, approximately 29% of initial responders to ONS became resistant by the final follow-up (p = 0.0253). The authors concluded that ONS is initially effective as a treatment for refractory CH, although a trend toward loss of efficacy was observed. No clear predictors of good clinical response were found in the present study. Conversely, DBS appears to be effective and provide a more stable clinical response over time with an acceptable rate of surgical complications.

A randomized, sham-controlled, parallel group, double-blind, safety and efficacy study at 21 headache centers in the USA was conducted by Goadsby et al. (2019). Eligible participants were aged 22 years or older and had chronic cluster headaches (at least four attacks per week) that were either previously or currently inadequately controlled with available therapies. Participants were randomly assigned (1:1) to receive either sphenopalatine ganglion stimulation (n=45) or sham stimulation (n=48). Thirty-six patients in the sphenopalatine ganglion stimulation group and 40 in the control group had at least one attack during the experimental phase and were included in efficacy analyses. The proportion of attacks for which pain relief was experienced at patients in the sphenopalatine ganglion stimulation group versus 38·87% (28·60-50·25) in the experimental phase and were included in efficacy analyses. The proportion of attacks for which pain relief was experienced at patients in the sphenopalatine ganglion stimulation group versus 38·87% (28·60-50·25) in the control group (odds ratio 2·62 [95% CI 1·28-5·34]; p=0·008). Nine serious adverse events were reported. Three of these serious adverse events were related to the implantation procedure (aspiration during intubation, nausea and vomiting, and venous injury or compromise). A fourth serious adverse event was an infection that was attributed to both the stimulation device and the implantation procedure. The other five serious adverse events were unrelated. The authors concluded that sphenopalatine ganglion stimulation seems efficacious and is well tolerated, and potentially offers an alternative approach to the treatment of chronic cluster headache. Further research is needed to clarify its place in clinical practice.

A monocenter, prospective, open-label, pilot trial (Birlea et al., 2019) explored the therapeutic utility and safety of external trigeminal neurostimulation (eTNS) as a preventive treatment in patients suffering from chronic migraine (CM). Participants were adult patients with a history of CM meeting International Classification of Headache Disorder-3 beta (2013) diagnostic criteria with or without medication overuse. After a 1-month baseline period, 58 patients applied at least one daily 20-min session of eTNS for 3 months. Primary outcomes were mean monthly changes in frequency of headache days and in overall acute headache medication intake. Compared to baseline, frequency of headache days decreased by 3.12 days (16.21%, p < 0.001) and acute medication intake decreased from 26.33 to 18.22 (30.81%, p <0.001) during the third month of treatment. Twenty-six patients reported 47 minor adverse events, of which only 2 were related to the use of the device (skin irritation under the electrode and headache worsening with vertigo). The authors concluded that this open-label pilot trial suggests that eTNS with the Cefaly® device is safe and effective as prophylactic treatment for CM in adult patients. The treatment effect is greatest in patients with noncontinuous headache; it is hardly significant in those with continuous headache. A limitation of the study is its open-label design and the lack of placebo arm. The fact that the number of daily eTNS sessions was not the same for all patients could be considered another weakness of the trial protocol, producing unnecessary variability.

A 2019 ECRI Health Technology Assessment on occipital nerve stimulation for treating medically refractory chronic cluster headache found that evidence from 6 small case series at high risk of bias is insufficient to determine how well ONS works or how it compares with other electrical stimulation options in patients with chronic CH that has not responded well to medical therapy. Side effects from ONS are common and include lead migration and local inflammation. Although studies reported

Occipital Neuralgia and Headache Treatment
UnitedHealthcare Commercial Medical Policy

Proprietary Information of UnitedHealthcare. Copyright 2020 United HealthCare Services, Inc.

Effective 07/01/2020
Tao et al. (2018) conducted a meta-analysis to analyze the effectiveness and safety of transcutaneous electrical nerve stimulation (TENS) on patients with migraine. The study included four randomized controlled trials, which compared the effect of TENS (n=161) with sham TENS (n=115). Change in the number of monthly headache days, responder rate, painkiller intake, adverse events and satisfaction were extracted as outcome. The authors concluded that there is low quality evidence suggesting that TENS may be effective in increasing responder rate, reducing headache days and painkiller intake, serving as a well-tolerated alternative for migraineurs. Future well-designed RCTs with extensive follow-up are needed.

An uncontrolled open-label prospective study was conducted by Miller et al. (2018). Thirty-one patients with intractable short-lasting unilateral neuralgiform headache attacks were treated with bilateral occipital nerve stimulation. At a mean follow-up of 44.9 months (range 13-89) there was a 69% improvement in attack frequency with a response rate (defined as at least a 50% improvement in daily attack frequency) of 77%. Attack severity reduced by 4.7 points on the verbal rating scale and attack duration by a mean of 64%. Improvements were seen in headache-related disability and depression. Adverse event rates were favorable, with no electrode migration or erosion reported. The authors concluded that occipital nerve stimulation appears to offer a safe and efficacious treatment for refractory short-lasting unilateral neuralgiform headache attacks. This is an uncontrolled study with a small sample size.

A retrospective review of 29 patients undergoing occipital nerve stimulation for occipital neuralgia from 2012 to 2017 at a single institution with a single neurosurgeon was conducted by Keifer et al. (2017). Of those 29 patients, 5 were repair or replacement of previous systems, 4 did not have benefit from trial stimulation, and 20 saw benefit to their trial stage of stimulation and went on to full implantation. There was an overall success rate of 85 percent in the 20 patients. The average preoperative 10-point pain score dropped from 7.4 ± 1.7 to a postoperative score of 2.9 ± 1.7. There were complications (4 patients), including infection, hardware erosion, loss of effect, and lead migration, which required revision or system removal. The authors concluded that despite complications, occipital nerve stimulation is a safe and effective procedure for refractory occipital neuralgia. The study is limited by its retrospective observations and small sample size.

Chen et al. (2015) conducted a systematic review to examine the effectiveness and adverse effects of occipital nerve stimulation (ONS) for chronic migraine. Five randomized controlled trials (RCTs) (total n = 402) and seven case series (total n = 115) met the inclusion criteria. All three multicenter RCTs included an initial blinded phase of 12 weeks, during which patients received either active or sham stimulation. Occipital nerve blocks and intraoperative testing were performed in the fourth center. The blinded phase was followed by an open label phase of 1–3 years during which all participants received active stimulation (results not yet published). Baseline migraine days per month were similar across the studies (20 to 23). Patients in the trials had between 19–22 days with prolonged, moderate or severe headache per month at baseline. Those patients receiving sham stimulation had a reduction of 2–4 days per month at three months. Meta-analysis shows that ONS was associated with an additional mean reduction of 2.59 days per month compared with sham control. Serious adverse events occurred in between 1% to 6% of patients in multicenter RCTs at 3 months and lead dislodgement and infections were common and often require revision surgery. Reported infection rates range from 4% to 30% with varied length of follow-up. The authors concluded that current evidence on the effectiveness and safety of ONS is still limited in quantity and remains inconclusive. Further measures to reduce the risk of adverse events and revision surgery are needed. The quantitative analysis was hampered by incomplete publication and reporting of trial data.

A prospective, long-term, open-label, uncontrolled observational study to evaluate the long-term efficacy and tolerability of occipital nerve stimulation (ONS) for medically intractable chronic migraine was performed by Rodrigo et al. (2017). Thirty-seven patients received the implantation of an ONS system after a positive psychological evaluation and a positive response to a preliminary occipital nerve blockage. The implantation was performed in 2 phases: a 10 day trial with implanted occipital leads connected to an external stimulator and, if more than 50% pain relief was obtained, permanent pulse generator implantation and connection to the previously implanted leads. After the surgery, the patients were evaluated annually using different scales: pain Visual Analogue Scale (VAS), number of migraine attacks per month, sleep quality, functionality in social and labor activities, reduction in pain medication, patient satisfaction, tolerability, and reasons for termination. The average follow-up time was 9.4 ± 6.1 years, and 31 patients completed a 7-year follow-up period. The VAS decreased by 4.9 ± 2.0 points. These results remained stable over the follow-up period. Five of the 35 permanently implanted patients with migraine attacks at baseline were free from these attacks at their last visits, whereas the pain severity decreased 3.8 ± 2.5 (according to the VAS) in the remaining patients. Seven of the 35 permanent implanted devices were definitively removed. The authors concluded that
the results achieved in this study suggested that ONS may provide long-term benefits for patients with medically intractable chronic migraine. Most patients experienced important improvements in some of the studied areas, such as migraine severity, frequency, sleep quality, concomitant medication intake, or social or work activities. Limitations of the current study include its uncontrolled and open-label design. Additionally, not all patients completed the 7-year follow-up period.

A randomized blind control study aimed to assess the effectiveness and safety of percutaneous electrical nerve stimulation (PENS) in migraine treatment was conducted by Li and Xu (2017). Sixty-two patients with at least 2 migration attacks each month were recruited and randomly divided into a PENS group and a sham PENS group in a ratio of 1:1. All patients received PENS or sham PENS 30 minutes daily, 5 times weekly for 12 weeks. All outcome measurements were performed at treatment initiation to establish a baseline and after 12 weeks of treatment. The authors report that at the end of the 12 weeks, the group receiving PENS exhibited statistically significant decrease in the mean in monthly migraine days (MMD) compared with the group receiving sham PENS intervention. The 50% responder rate (RR) was significantly higher in the PENS group than that in the sham PENS group. The monthly migraine attacks (MMA), monthly headache days (MHD), and monthly acute antimigraine drug intake (MAADI) were also significantly lower in the PENS group that those in the sham PENS group. The authors concluded that the results of the study demonstrated that PENS is more effective and safer than Sham PENS for the treatment of migraine. Follow-up regarding both short and long-term effectiveness of PENS for treatment of migraine still needs to be assessed.

Liu et al. (2017) performed a randomized, controlled trial of transcutaneous occipital nerve stimulation (tONS) for prevention of migraine to evaluate the efficacy and tolerability of tONS in patients with migraine. Patients (n = 110) were randomized to 1 of 5 therapeutic groups before treatment for 1 month. Groups A through C received tONS at different frequencies, group D underwent sham tONS intervention, and group E received topiramate orally. The authors report that the 50% responder rate was significantly greater in the groups undergoing active tONS and topiramate, compared with sham-treated group. A significant reduction in headache intensity was noted in each test group compared with the sham group. They concluded that tONS therapy is a new promising approach for migraine prevention. It has infrequent and mild adverse events and may be effective among patients who prefer nonpharmacological treatment. The findings of this study need to be validated by well-designed studies with long-term follow-up.

Miller et al. (2017) analyzed 51 subjects to evaluate the long-term outcomes of highly intractable chronic cluster headache with occipital nerve stimulation. Patients with intractable chronic cluster headache were implanted with occipital nerve stimulators during the period 2007-2014. The primary endpoint was improvement in daily attack frequency. Secondary endpoints included attack severity, attack duration, quality-of-life measures, headache disability scores and adverse events. The mean follow-up was 39.17 (range 2-81) months. Nineteen patients had other chronic headache types in addition in chronic cluster headache. At final follow-up, there was a 46.1% improvement in attack frequency across all patients, 49.5% in those with cluster headache alone and 40.3% in those with multiple phenotypes. There were no significant differences in response in those with or without multiple headache types. The overall response rate (defined as at least a 50% improvement in attack frequency) was 52.9%. Reductions were also seen in attack duration and severity. Improvements were noted in headache disability scores and quality-of-life measures. The authors concluded that occipital nerve stimulation appears to be a safe and efficacious treatment for highly intractable chronic cluster headache even after a mean follow-up of over 3 years. This study was uncontrolled and unblinded, and had an inadequate sample size.

Mekhail et al. (2016) presented 52-week safety and efficacy results from an open-label extension of a randomized, sham-controlled trial for patients with chronic migraine (CM) undergoing peripheral nerve stimulation of the occipital nerves. In this single center, 20 patients were implanted with a neurostimulation system, randomized to an active or control group for 12 weeks, and received open-label treatment for an additional 40 weeks. Outcomes collected included number of headache days, pain intensity, Migraine Disability Assessment (MIDAS), Zung Pain and Distress (PAD), direct patient reports of headache pain relief, quality of life, satisfaction, and adverse events (AEs). Headache days per month were reduced by 8.51 (± 9.81) days. The proportion of patients who achieved a 30% and 50% reduction in headache days and/or pain intensity was 60% and 35%, respectively. MIDAS and Zung PAD were reduced for all patients. Fifteen (75%) of the 20 patients at the site reported at least one AE. A total of 20 AEs were reported from the site. The authors concluded that occipital nerve stimulation appears to be a safe and efficacious treatment for chronic cluster headache even after a mean follow-up of over 3 years. This study was uncontrolled and had an inadequate sample size.

A 2015 National Institute for Health and Care Excellence (NICE) guideline for the implantation of a sphenopalatine ganglion stimulation device for chronic cluster headache has the following states that current evidence on the efficacy of implantation of
a sphenopalatine ganglion stimulation device for chronic cluster headache, in the short term (up to 2 months), is adequate. A variety of complications have been documented, most of which occur early and resolve; surgical revision of the implanted system is sometimes needed. The procedure should only be used with special arrangements for clinical governance, consent and audit or research. NICE encourages further research on sphenopalatine ganglion stimulation for chronic cluster headache (NICE, 2015).

Dodick et al. (2014) presented 52-week safety and efficacy results of peripheral nerve stimulation (PNS) of the occipital nerves for managing chronic migraine from an open-label extension of a randomized, sham-controlled trial. In this institutional review board-approved, randomized, multicenter, double-blinded study, patients were implanted with a neurostimulation system, randomized to an active or control group for 12 weeks, and received open-label treatment for an additional 40 weeks. Statistical tests assessed change from baseline to 52 weeks using paired t-tests. Intent-to-treat (ITT) analyses of all patients (N = 157) and analyses of only patients who met criteria for intractable chronic migraine (ICM; N = 125) were performed. Headache days were significantly reduced by 6.7 (± 8.4) days in the ITT population and by 7.7 (± 8.7) days in the ICM population. The percentages of patients who achieved a 30% and 50% reduction in headache days and/or pain intensity were 59.5% and 47.8%, respectively. Migraine disability assessment (MIDAS) and Zung Pain and Distress (PAD) scores were significantly reduced for both populations. Excellent or good headache relief was reported by 65.4% of the ITT population and 67.9% of the ICM population. More than half the patients in both cohorts were satisfied with the headache relief provided by the device. A total of 183 device/procedure-related adverse events occurred during the study, of which 18 (8.6%) required hospitalization and 85 (40.7%) required surgical intervention; 70% of patients experienced an adverse event. The authors concluded that the results of the study supported the 12-month efficacy of PNS of the occipital nerves for headache pain and disability associated with chronic migraine. Because of the significant complication rate, more emphasis on adverse event mitigation is needed in future research.

Ducic et al. (2013) systematically compared the outcomes of different types of interventional procedures offered for the treatment of headaches and targeted toward peripheral nerves based on available published literature. The objective of this study was to systematically review the literature to compare the published outcomes and effectiveness of peripheral nerve surgery, radiofrequency (RF) therapy, and peripheral nerve stimulators for chronic headaches, migraines, and occipital neuralgia. A total of 26 studies met the inclusion criteria. Of these, 14 articles studied nerve decompression, 9 studied peripheral nerve stimulation, and 3 studied RF intervention. When study populations and results were pooled, a total of 1253 patients had undergone nerve decompression with an 86% success rate, 184 patients were treated by nerve stimulation with a 68% success rate, and 131 patients were treated by RF with a 55% success rate. neither nerve decompression nor RF reported complications requiring a return to the operating room, whereas implantable nerve stimulators had a 31.5% rate of such complications. The authors concluded that although peripheral nerve surgery seems to be the interventional treatment modality that is currently best supported by the literature, better controlled and normalized high-quality studies will help to better define the specific roles for each type of intervention.

In a systematic review, Jasper and Hayek (2008) evaluated the strength of evidence that occipital nerve stimulation (ONS) is an effective treatment of chronic headache. Ten observational studies, of which 4 were prospective, and a number of case series, case reports, and reviews were identified. No randomized controlled trials (RCT) were identified. All of the studies reported positive outcomes including improved pain relief, reduced frequency, intensity, and duration of headaches with reduced medication consumption. ONS was reportedly successful for 70 to 100% of patients. Reduction of pain in patients with occipital headaches and transformed migraine is significant and rapid; for cluster patients the improvement may be less dramatic and it may take several months of occipital stimulation to achieve relief. No long-term adverse events occurred. Several short-term adverse events occurred including infection, lead displacement, and battery depletion. The body of evidence as a whole is a level of strength of IV (limited).

Vadivelu et al. (2011) evaluated 18 patients with Chiari I malformation (CMI) and persistent occipital headaches who underwent occipital neurostimulator trials and, following successful trials, permanent stimulator placement. Seventy-two percent (13/18) of patients had a successful stimulator trial and proceeded to permanent implant. Of those implanted, 11/13 (85%) reported continued pain relief at a mean follow-up of 23 months. Device-related complications requiring additional surgeries occurred in 31% of patients. According to the authors, occipital neuromodulation may provide significant long-term pain relief in selected CMI patients with persistent occipital pain. The authors state that larger and longer-term studies are needed to further define appropriate patient selection criteria as well as to refine the surgical technique to minimize device-related complications.
Popeney et al. (2003) evaluated the responses to C1 through C3 peripheral nerve stimulation in an uncontrolled consecutive case series of 25 patients with transformed migraine. Prior to stimulation, all patients experienced severe disability with 75.56 headache days over a 3-month period. Following stimulation, 15 patients reported little or no disability, 1 reported mild disability, 4 reported moderate disabilities, and 5 continued with severe disability, with 37.45 headache days. The average improvement in the MIDAS score was 88.7%, with all patients reporting their headaches well controlled after stimulation. The authors concluded that these results raise the possibility that C1 through C3 peripheral nerve stimulation can help improve transformed migraine symptoms and disability. The authors stated that a controlled study is required to confirm these results.

Magis et al. (2011) evaluated 15 patients with drug-resistant chronic cluster headache (dCCH) who were implanted with suboccipital stimulators on the side of their headache. Long-term follow-up was achieved by questionnaires or by phone interviews. Mean follow-up time post-surgery was 36.82 months (range 11 - 64 months). One patient had an immediate post-operative infection of the material. Among the 14 remaining patients, 11 (i.e., 80%) had at least a 90% improvement with 60% becoming pain-free for prolonged periods. Two patients did not respond or described mild improvement. According to the authors, long-term follow-up confirms the efficacy of ONS in dCCH, which remains a safe and well-tolerated technique. These findings require confirmation in a larger study.

In a set of recommendations regarding neuromodulation for the treatment of chronic headaches, the European Headache Federation states that in spite of a growing field of stimulation devices in headaches treatment, further controlled studies to validate, strengthen and disseminate the use of neurostimulation are clearly warranted. The European Headache Federation states that until these data are available any neurostimulation device should only be used in patients with medically intractable syndromes from tertiary headache centers either as part of a valid study or have shown to be effective in such controlled studies with an acceptable side effect profile (Martelletti et al. 2013).

Slavin et al. (2006) analyzed the records of 14 consecutive patients with intractable occipital neuralgia treated with peripheral neurostimulation. Ten patients proceeded with system internalization after a 50% pain reduction during the trial period. Two patients had their systems explanted because of loss of stimulation effect or significant improvement of pain, and one patient had part of his hardware removed because of infection. The authors concluded that overall, the beneficial effect from chronic stimulation persisted in more than half of the patients for whom the procedure was considered and in 80% of those who significantly improved during the trial and proceeded with internalization. These findings require confirmation in a larger study.

Amin et al. (2008) evaluated the efficacy of supraorbital nerve stimulation for treatment of intractable supraorbital neuralgia in a case series of 16 patients. The patients underwent a trial of supraorbital nerve stimulation, and efficacy was assessed after 5-7 days. Ten patients consented to undergo permanent implantation of the stimulator. Opioid consumption and headache scores were monitored preoperatively and at timed intervals for 30 weeks. Headache scores decreased, and opioid consumption was reduced in half, and these beneficial accomplishments were maintained up to 30 weeks after implantation. This study is limited by a short follow-up.

The National Institute for Health and Care Excellence (NICE) stated that the evidence on occipital nerve stimulation (ONS) for intractable chronic migraine shows some efficacy in the short term but there is very little evidence about long-term outcomes. With regard to safety, there is a risk of complications, needing further surgery. Therefore, NICE recommends that this procedure should only be used with special arrangements for clinical governance, consent, and audit or research. NICE encourages publication of further information from comparative studies and from collaborative data collection to guide future use of this procedure and to provide patients with the best possible advice (NICE 2013).

**Professional Societies**

**American Society of Anesthesiologists (ASA)/American Society of Regional Anesthesia and Pain Medicine (ASRA)**

In practice guidelines created jointly in 2010, the American Society of Anesthesiologists (ASA) and American Society of Regional Anesthesia and Pain Medicine (ASRA) state the following: "Subcutaneous peripheral nerve stimulation may be used in the multimodal treatment of patients with painful peripheral nerve injuries who have not responded to other therapies" (ASA/ASRA, 2010).
American Headache Society (AHS)

AHS has issued a statement about surgical intervention in migraine treatment that indicates that surgery for migraine is a last-resort option and is probably not appropriate for most sufferers. According to the American Headache Society, there are no convincing or definitive data, to date, that show its long-term value. Besides replacing the use of more appropriate treatments, surgical intervention also may produce side effects that are not reversible and carry the risks associated with any surgery (AHS 2012).

A 2016 AHS guideline for treatment of cluster headaches recommend (Level A) sumatriptan subcutaneous, zolmitriptan nasal spray, and high flow oxygen for acute treatment. Sphenopatine ganglion stimulation has been administered a Level B recommendation for acute treatment. Suboccipital steroid injections have emerged as the only treatment to receive a Level A recommendation. Other newly evaluated treatments have been given a Level B recommendation (negative study: deep brain stimulation), a Level C recommendation (positive study: warfarin; negative studies: cimetidine/chlorpheniramine, candesartan), or a Level U (data inadequate or conflicting) recommendation (frovatriptan). Further studies are warranted to demonstrate safety and efficacy for established and emerging therapies (Robbins et al., 2016).

A 2019 AHS position statement on integrating new migraine treatments into clinical practice states neuromodulation and biobehavioral therapy may be appropriate for preventive and acute treatment, depending on the needs of individual patients. Neuromodulation may be useful for patients who prefer nondrug therapies or who respond poorly, cannot tolerate, or have contraindications to pharmacotherapy (AHS, 2019).

American Society of Interventional Pain Physicians (ASIPP)

A 2013 ASIPP guideline recommends that “therapeutic neurotomy may be provided based on the response from controlled diagnostic blocks.”

Congress of Neurological Surgeons

The Congress of Neurological Surgeons published an evidence-based guideline in 2015 supporting the use of occipital nerve stimulation as a treatment option for patients with medical refractory occipital neuralgia. The patient population in the nine studies reviewed was small and there was a short duration of follow-up (Sweet, 2015). Class III evidence: Level III recommendation (Evidence from case series, comparative studies with historical controls, case reports, and expert opinion, as well as significantly flawed randomized, controlled trials).

International Neuromodulation Society (INS)

The INS board of directors chose an expert panel, the Neuromodulation Appropriateness Consensus Committee (NACC), to evaluate the peer-reviewed literature, current research, and clinical experience and to give guidance for the appropriate use of these methods. The NACC found that evidence supports extracranial stimulation for facial pain, migraine, and scalp pain but is limited for intracranial neuromodulation (Deer et al. 2014).

U.S. Food and Drug Administration (FDA)

This section is to be used for informational purposes only. FDA approval alone is not a basis for coverage.

Local Injection Therapy

Various local anesthetics are approved by the FDA for use in diagnostic and therapeutic nerve blockade. Botulinum toxin-A (BTX-A or BOTOX) is a neurolytic agent that has also been approved by the FDA for treatment of some conditions. However, BTX-A is not specifically approved for treatment of cervicogenic headache or occipital neuralgia; the use of BTX-A for these diagnoses is off-label use.

Radiofrequency Ablation (RFA)

RFA is a procedure and, therefore, is not subject to regulation by the FDA. However, the devices used to perform RFA are regulated by the FDA premarket approval process. There are numerous devices listed in the FDA 510(k) database approved for use in performing RFA. Two product codes are dedicated to these devices, one for radiofrequency lesion generators (GXD) and

**Electrical Stimulation**

Electrical stimulation of the occipital/cranial nerves for the treatment of occipital neuralgia, cervicogenic headache and migraines is a procedure and, therefore, not subject to regulation by the FDA; however, the devices used to perform electrical stimulation are regulated via the FDA 510(k) premarket approval process. There are numerous devices listed in the FDA 510(k) database with product codes GZF, GZB and PCC. Additional information is available at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm. (Accessed April 26, 2020)

**Centers for Medicare and Medicaid Services (CMS)**

Medicare does not have a National Coverage Determination (NCD) for the injection of local anesthetics and/or steroid used for treatment of occipital neuralgia. Local Coverage Determinations (LCDs) exist; see the LCDs for [Peripheral Nerve Blocks](#).

Medicare does not have NCDs or LCDs for the following procedures used to treat and/or diagnose occipital neuralgia or headaches (migraine and cervicogenic):

- Occipital neurectomy
- Partial posterior intradural C1-C3 rhizotomy
- Radiofrequency ablation (thermal or pulsed) or denervation
- Rhizotomy of C1-C3 spinal dorsal roots
- Surgical decompression of second cervical nerve root and ganglion
- Surgical decompression of the greater occipital nerve

Medicare does not have NCDs for neurostimulation used in treatment of occipital neuralgia. Local Coverage Determinations (LCDs) exist; see the LCDs for [Peripheral Nerve Stimulation](#).

(Accessed May 7, 2020)

**References**


---

**Policy History/Revision Information**

<table>
<thead>
<tr>
<th>Date</th>
<th>Summary of Changes</th>
</tr>
</thead>
<tbody>
<tr>
<td>08/01/2020</td>
<td><strong>Template Update</strong></td>
</tr>
<tr>
<td></td>
<td>● Reformatted policy; transferred content to new template</td>
</tr>
<tr>
<td>07/01/2020</td>
<td><strong>Applicable Codes</strong></td>
</tr>
<tr>
<td></td>
<td>● Removed CPT code 62281</td>
</tr>
<tr>
<td></td>
<td><strong>Supporting Information</strong></td>
</tr>
<tr>
<td></td>
<td>● Updated <em>Clinical Evidence, CMS, and References</em> sections to reflect the most current information</td>
</tr>
<tr>
<td></td>
<td>● Archived previous policy version 2020T0080DD</td>
</tr>
</tbody>
</table>
Instructions for Use

This Medical Policy provides assistance in interpreting UnitedHealthcare standard benefit plans. When deciding coverage, the member specific benefit plan document must be referenced as the terms of the member specific benefit plan may differ from the standard plan. In the event of a conflict, the member specific benefit plan document governs. Before using this policy, please check the member specific benefit plan document and any applicable federal or state mandates. UnitedHealthcare reserves the right to modify its Policies and Guidelines as necessary. This Medical Policy is provided for informational purposes. It does not constitute medical advice.

This Medical Policy may also be applied to Medicare Advantage plans in certain instances. In the absence of a Medicare National Coverage Determination (NCD), Local Coverage Determination (LCD), or other Medicare coverage guidance, CMS allows a Medicare Advantage Organization (MAO) to create its own coverage determinations, using objective evidence-based rationale relying on authoritative evidence (Medicare IOM Pub. No. 100-16, Ch. 4, §90.5).

UnitedHealthcare may also use tools developed by third parties, such as the MCG™ Care Guidelines, to assist us in administering health benefits. UnitedHealthcare Medical Policies are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.